优化TBI-223的剂量,以提高治疗效益,与抗结核治疗方案中的linezolid相比
Natasha Strydom1, Jacqueline P Ernest1, Marjorie Imperial1
1Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy, University of California, San Francisco, CA, USA.
Nature communications
|August 24, 2024
概括
一种新的结核病药物TBI-223有望提高疗效和安全性. 在bedaquiline, pretomanid和linezolid (BPaL) 方案中优化剂量可能会在两个月内导致90%以上的培养转化.
科学领域:
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
- 药物开发 药物开发
背景情况:
- 结核病 (TB) 治疗需要新药,因为耐药性不断增加.
- 虽然线索利德是有效的,但在结核病治疗方案中存在安全问题.
- 贝达基林,普雷托曼尼德和线索利德 (BPaL) 疗法是现代结核病治疗的基石.
研究的目的:
- 为了优化TBI-223的剂量,BPaL疗法中的一种新型氧化丁.
- 在临床前结核病模型中,评估TBI-223与linezolid的疗效和安全性.
- 使用转化平台预测临床结果并完善TBI-223的剂量.
主要方法:
- 临床前研究包括单疗法,多药疗法和病变透实验.
- 开发一个翻译平台,整合来自4项试验的临床前和临床数据.
- 将TBI-223临床前和第一期临床试验数据应用于翻译框架.
主要成果:
- 在临床前模型中,TBI-223的疗效和安全性与linezolid相似.
- 翻译平台成功预测了临床结果.
- 在BPaL疗法中,预计每日剂量为1200-2400毫克的TBI-223可以达到高的培养转化率.
结论:
- 在BPaL疗法中优化TBI-223剂量显示出在结核病治疗中改善治疗结果的潜力.
- 预计超过90%的患者在两个月内通过优化方案实现培养转换.
- TBI-223代表了改善结核病治疗疗效和安全性的有希望的候选人.
相关概念视频
01:28Pulmonary Tuberculosis V
174
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
174
01:29Pulmonary Tuberculosis I
227
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
227
01:27Combined Effects of Drugs: Synergism
3.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.8K
01:26Pulmonary Tuberculosis IV
134
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
134